Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Free Cash Flow for 9 consecutive years, with -$90.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 22.23% to -$90.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$412.6 million, a 18.26% decrease, with the full-year FY2025 number at -$412.6 million, down 18.26% from a year prior.
  • Free Cash Flow was -$90.6 million for Q4 2025 at Denali Therapeutics, up from -$105.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$39.2 million in Q2 2022 to a low of -$132.0 million in Q1 2025.
  • A 5-year average of -$79.5 million and a median of -$75.1 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 83407.14% in 2021, then skyrocketed 32.25% in 2024.
  • Denali Therapeutics' Free Cash Flow stood at -$60.6 million in 2021, then decreased by 21.77% to -$73.8 million in 2022, then crashed by 42.69% to -$105.4 million in 2023, then rose by 29.69% to -$74.1 million in 2024, then fell by 22.23% to -$90.6 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Free Cash Flow are -$90.6 million (Q4 2025), -$105.9 million (Q3 2025), and -$84.2 million (Q2 2025).